The Viral Etiology of Skin Cancer  by Meyers, Jordan M. & Munger, Karl
CUTANEOUS MALIGNANCY
The Viral Etiology of Skin Cancer
Jordan M. Meyers1 and Karl Munger1,2
1Division of Infectious Diseases, Brigham and Women’s Hospital, Department of Medicine and Program in Virology, Harvard Medical School, Boston,
Massachusetts, USA
Correspondence: Karl Munger, E-mail: karl.munger@tufts.edu
2Present Address: Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA
doi:10.1038/skinbio.2014.6
The concept that viruses may be
etiological agents of cancers is as old
as the discovery of viruses themselves.
In 1908, 3 years before Peyton Rous
was passaging what later became to be
known as Rous Sarcoma Virus in
chickens, two Danish scientists, Eller-
man and Bang, were characterizing a
transmissible filtrate that reproducibly
caused leukemia in chickens. These
findings were received with harsh
skepticism, and the scientific commu-
nity did not universally accept the
concept that tumors could be caused
by transmissible agents. Richard Shope,
a colleague of Peyton Rous at the
Rockefeller Institute, identified an infec-
tious agent that infected cottontail
rabbits. It caused cutaneous papillomas
that could grow to be quite large and
which may be the basis of sightings of
the mystical and ravenous ‘‘Jackelope’’
of southwestern American lore. Shope
later collaborated with Rous to demon-
strate that exposure of these papillomas
to coal tar or infection of a host that
does not support viral replication caused
malignant progression to skin cancers.
This infectious agent, the cottontail
rabbit papillomavirus or Sylvilagus
floridanus Papillomavirus 1, was the
first virus linked to a cancer in a mam-
malian host (Javier and Butel, 2008;
Moore and Chang, 2010) (Figure 1).
PAPILLOMAVIRUSES
Papillomaviruses are small, non-envel-
oped viruses with double-stranded
circular DNA genomes of approxi-
mately 8,000 bp in size. Transcription
is unidirectional, i.e., only one of the
two strands is known to encode genetic
information. Papillomavirus genomes
consist of three major regions: an early
region that encodes five to seven non-
structural, regulatory ‘‘E’’ open reading
frames, the late region encoding the
major and minor capsid proteins, L1
and L2, respectively, and a non-coding
region referred to as the ‘‘long control
region’’, which contains sequences that
regulate viral gene transcription and
genome replication. Papillomaviruses
have been detected throughout the
animal kingdom. They are highly spe-
cies specific and infect squamous
epithelia. Papillomaviruses have been
classified based on the degree of
sequence identity and are referred to
as genotypes. More than 170 human
papillomavirus types have been char-
acterized and most of them fall within
the alpha, beta, gamma, and, mu genera
(Bernard et al., 2010).
BETA HUMAN PAPILLOMAVIRUSES AND
NON-MELANOMA SKIN CANCERS
Around the same time that Shope and
Rous discovered that cottontail rabbit
papillomavirus caused skin cancers in
rabbits, Felix Lewandowsky and Wil-
liam Lutz described a rare skin disorder
that would be known as epidermodys-
plasia verruciformis (EV; Lewandowski
and Lutz, 1922). EV patients develop
widespread wart-like lesions that can
cover entire portions of their skin
and frequently develop malignant skin
tumors, particularly at sun-exposed
areas. Seminal work by Stefania
Jablonska and Gerard Orth linked
human papillomavirus (HPV) infec-
tions with skin lesions and cancers in
EV patients (Orth et al., 1978). This work
predates Harald zur Hausen’s discovery
of the mucosal-specific alpha-type
HPVs, HPV16, and HPV18, as etiolo-
gical agents of cervical carcinoma. EV
patients suffer from a deficiency that
prevents effective clearance of beta HPV
infections. Interestingly, however, EV
patients do not seem to be at a higher
risk for bacterial or other viral infec-
tions, including alpha HPV infections
(Gewirtzman et al., 2008).
The genetic basis of EV was discovered
in 2002 when Favre and colleagues dis-
covered that EV patients harbored muta-
tions in either one of two adjacent genes,
TMC6 or TMC8, on chromosome 17
(Ramoz et al., 2002). These genes encode
the transmembrane proteins, EVER1 and
EVER2, which localize to endoplasmic
reticulum membranes and may be
involved in intracellular zinc transport.
How this relates to susceptibility to
persistent cutaneous HPV infections
remains to be fully delineated.
Beta HPV genomes can readily be
detected in tumor cells of EV patients
and also are likely etiologic agents of
non-melanoma skin cancers (NMSCs)
that arise in chronically immune-
suppressed patients (Majewski and
Jablonska, 2002; Proby et al., 2011;
Iannacone et al., 2013; Neale et al.,
2013). Whether or not beta HPV infec-
tions also contribute to NMSCs in other
patients has been a matter of debate,
mostly because subclinical beta HPV
infections are very widespread and not
every tumor cell is HPV positive in
these patients (Arron et al., 2011). As
detailed below, this does not rule out,
however, that infections with some
beta HPVs may be drivers of NMSC
initiation in the general population.
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MECHANISTIC CONTRIBUTIONS OF BETA
HPVS TO NMSC DEVELOPMENT
Most of the fundamental concepts of
how HPVs contribute to human cancer
formation have been established by
studies with alpha HPVs, which prefer-
entially infect mucosal epithelia. These
HPVs have been studied extensively and
they fall into ‘‘high-risk’’ and ‘‘low-risk’’
groups based on their propensities to
cause lesions that can undergo malig-
nant progression. Notably, high-risk
alpha HPV infections cause almost all
cases of cervical carcinomas, a signifi-
cant fraction of other anogenital tract
tumors as well as oropharyngeal cancers.
Overall, approximately, 5% of all human
cancers are caused by high-risk alpha
HPV infections. These cancers regularly
maintain viral gene expression; every
tumor cell generally contains and ex-
presses HPV sequences, and they remain
‘‘addicted’’ to expression of the E6 and
E7 oncogenes. The high-risk alpha HPV
E6 and E7 proteins target and function-
ally compromise the p53 and retinoblas-
toma (pRB) tumor suppressors, respect-
ively, which are frequently mutated in
non-HPV-associated cancers.
It has been proposed that beta HPVs
may be similarly classified into ‘‘high-
risk’’ and ‘‘low-risk’’ groups. HPV5 and
the phylogenetically related HPV8
have been originally isolated from
NMSCs arising in EV patients (Fuchs
et al., 1986; Zachow et al., 1987).
Hence, these viruses may be consi-
dered ‘‘high-risk’’ for NMSC develop-
ment in EV patients. Experiments with
transgenic mice are consistent with this
model. Expression of the early coding
region of HPV8 from the basal
keratinocyte-specific keratin 14 promoter
causes spontaneous development of
malignant skin tumors in transgenic
mice (Schaper et al., 2005). Addi-
tional studies revealed that HPV8 E6
and, surprisingly, E2, scored as the
major transforming proteins in this
model (Pfefferle et al., 2008; Marcuzzi
et al., 2009). While these tumors will
arise spontaneously, UV irradiation
dramatically accelerates carcinogenesis,
thereby recapitulating a key risk factor
of EV-associated cancers.
Unlike what has been reported for
high-risk alpha HPVs, the HPV5 and
HPV8 E7 proteins only weakly asso-
ciate with and do not destabilize
pRB, and similarly the E6 proteins do
directly inhibit p53 activity (Caldeira
et al., 2003; Rozenblatt-Rosen et al.,
2012; White et al., 2012a, b). HPV5
and HPV8 E6 proteins, however, have
been reported to inhibit proapoptotic
factors activated during UV damage
and impair DNA damage response
pathways. Several groups have reported
that beta HPV E6 proteins can trigger
the degradation of the proapoptotic
BCL2 family member BAK through a
proteasome-dependent pathway (Jackson
et al., 2000; Underbrink et al., 2008).
BAK is normally retained in the mito-
chondria but is released and induces
apoptosis following UV exposure.
BAK degradation in beta HPV-
infected cells may, therefore, blunt
the apoptotic response to UV irradia-
tion and allow survival of cells that
have suffered extensive DNA damage
and possibly acquired oncogenic
mutations.
There is evidence that the repair of
UV-induced DNA damage is inhibited
in HPV8 E6 expressing cells (Simmonds
and Storey, 2008; Underbrink et al.,
2008). HPV5 and HPV8 E6 proteins
also inhibit double-strand DNA break
repair by associating with and desta-
bilizing the histone acetyl transferase,
p300 (Howie et al., 2011; Wallace
et al., 2012), which can regulate
activity of the ATM/ATR kinases by
acetylation. Similar to subverting
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Figure 1. Milestones in the viral etiology of skin cancer. Major discoveries in the field are indicated on a time scale. See text for details and references.
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apoptosis signaling though BAK degra-
dation, blunting DNA break repair may
allow for accumulation of mutations
in beta HPV-infected cells, thereby
facilitating malignant progression.
According to such a model, beta HPV
infections contribute to cancer initia-
tion in non-EV patients through a ‘‘hit-
and-run’’ mechanism, and as viral gene
expression may not be necessary for
the maintenance of the transformed
state, it might explain why the viral
genome is not detected in all tumor
cells (Arron et al., 2011).
HPV5 or HPV8 E6 expression in
transgenic mice or in organotypic
tissue culture models of skin dramati-
cally inhibits epithelial differentiation
(Akgul et al., 2007; Marcuzzi et al.,
2009). This ability of E6 to uncouple
the processes of epithelial differen-
tiation and proliferation may be
relevant to the viral life cycle, as viral
genome synthesis and progeny forma-
tion is restricted to terminally differ-
entiated cells that have normally
withdrawn from the proliferative pool.
As HPVs require cellular DNA syn-
thesis for the replication of their
genomes, it is essential that cell cycle
proficiency be maintained during
differentiation. One of the critical
regulators of epithelial differentiation
is NOTCH signaling. Several recent
studies have shown that the HPV5 and
HPV8 E6 proteins inhibit NOTCH
signaling by interacting with MAML
proteins, critical co-activators of the
NOTCH transcription complex (Brimer
et al., 2012; Rozenblatt-Rosen et al.,
2012; Tan et al., 2012; Meyers et al.,
2013). NOTCH has tumor suppressor
activities in epithelia, and inactivating
NOTCH pathway mutations are highly
prevalent in SCCs (Agrawal et al.,
2011; Stransky et al., 2011).
HPV5 E6 has also been shown to
inhibit TGF (transforming growth fac-
tor)-beta signaling in keratinocytes
through destabilization of the SMAD3/
4 transcriptional complex (Mendoza
et al., 2006). Similar to NOTCH, TGF-
beta signaling can be oncogenic or
tumor suppressive in different tissues
and/or at different stages of carcino-
genesis. Future work will help to
unravel how disruption of NOTCH
and/or TGF-beta signaling may contri-
bute to the life cycle of beta HPV and/
or contribute to NMSC formation.
The E6 and E7 proteins of other beta
HPVs, including HPV types 20, 27, and
38, also exhibit carcinogenic activities
in transgenic mouse models, although,
and in contrast to the HPV8 model,
tumor formation was strictly dependent
on UV exposure (Dong et al., 2005;
Michel et al., 2006; Viarisio et al.,
2011). HPV38 has been studied in
some detail, and in contrast to many
other beta HPVs, HPV38 can immor-
talize primary human epithelial cells
and has transforming activities in vitro.
Unlike HPV5 and HPV8, HPV38 E6
has been reported to cause p53
inactivation, and HPV38 E7 has been
shown to efficiently associate with pRB
and trigger its degradation (Caldeira
et al., 2003; Accardi et al., 2006).
These activities of the HPV38 E6 and
E7 proteins are somewhat reminiscent
of cervical cancer associated, high-risk
alpha HPVs. Whether humans infected
with HPV38 are at a particularly high
risk for NMSC development remains to
be determined.
MERKEL CELL CARCINOMA
Merkel cell carcinoma (MCC) is a
highly metastatic, aggressive skin can-
cer, whose occurrence is on the rise.
Merkel cells were first described over a
100 years ago by Friederich Sigmund
Merkel, and they are involved in fine
touch sensing and are detected
throughout the epithelium in cutaneous
skin. Although originally thought to be
derived from the neural crest, Merkel
cells express specific cytokeratin mar-
kers and may be of an epithelial
lineage (Bardot et al., 2013). An infec-
tious etiology has been suggested for
MCCs as they are more prevalent in
immunosuppressed patients, and seque-
nces corresponding to a previously
unknown human polyomavirus, Merkel
cell polyomavirus (MCPyV) were isola-
ted from MCCs in 2008 (Feng et al.,
2008). It is now generally accepted that
the vast majority of MCCs harbor
MCPyV sequences (Rodig et al., 2012).
Polyomaviruses, particularly the
simian vacuolating virus 40, have been
studied extensively. Polyomaviruses
are similar to papillomaviruses in that
they contain small double-stranded
DNA genomes, but they have a distinct
genomic organization. In contrast to
papillomaviruses, polyomavirus early
and late genes are encoded on different
strands of the genome, and the MCPyV
early region encodes three major pro-
teins through alternative splicing: small
and large tumor antigens (T antigen) as
well as a more recently identified
splice variant that has been referred to
as ALTO (Carter et al., 2013). MCPyV
sequences are commonly found inte-
grated in MCCs, resulting in C-terminal
truncation of large T antigen as well as
ALTO (DeCaprio and Garcea, 2013).
Both small T antigen and the truncated
large T antigen proteins are thought to
contribute to the tumorigenicity of
MCPyV, though there is still debate
on whether small T antigen is required
for tumor maintenance and the
potential role of ALTO remains to be
determined (Angermeyer et al., 2013;
Shuda et al., 2013). MCPyV large
T antigen shares biological activities
with simian vacuolating virus 40 large
T antigen and binds pRB, but the
growth promoting activity for MCPyV
large T antigen is only seen with the
tumor-associated truncation mutants
(Cheng et al., 2013). MCPyV small
T antigen is a potent oncogene, as it
can induce anchorage- and contact-
independent growth of rodent fibro-
blasts and decrease the serum require-
ment of human cells (Shuda et al.,
2011). Current research is focused on
identifying the mechanistic basis of
the unique carcinogenic activity of
MCPyV. Serology studies suggest that
similar to beta HPVs, MCPyV
infections appear to be frequent and
occur in early childhood (DeCaprio
and Garcea, 2013), but it is unknown
whether MCPyV can establish a low-
level life-long persistent infection and,
if so, whether the initial infection
and/or the persistently infected reservoir
involve Merkel cells. In summary,
MCPyV-associated MCCs similar to
beta HPV-associated NMSCs represent
very rare and atypical outcomes of very
frequent infections.
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